SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Hossein Borghaei

Hossein Borghaei

Fox Chase Cancer Center, Philadelphia

Dr. Hossein Borghaei is Chief of the Division of Thoracic Medical Oncology and the Gloria and Edmund M. Dunn Chair in Thoracic Oncology at Fox Chase Cancer Center in Philadelphia, United States. His research centers on immunotherapy and antibody-based and targeted therapies for non-small cell lung cancer and malignant pleural mesothelioma. He was first author of the practice-changing CheckMate-057 nivolumab trial and an investigator on CheckMate-227, co-directs the Immune Monitoring Facility, and serves on scientific advisory and governance bodies for the American Lung Association and AACR. He is a frequent speaker at major international thoracic oncology congresses.

Connect

Hossein Borghaei

Featured in

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates